Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Clene Inc (NQ: CLNN )

3.960 -0.130 (-3.18%)
Streaming Delayed Price Updated: 11:56 AM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 69,790
Open 4.100
Bid (Size) 3.960 (1)
Ask (Size) 4.130 (7)
Prev. Close 4.090
Today's Range 3.900 - 4.180
52wk Range 3.818 - 12.00
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Reports Q3 2024 Results and Progress on ALS Treatment Pathway
Via Investor Brand Network
Exposures Product Safety
European Commission Imposes Hefty Fine on Firm for Blocking Rival MS Drug Developer
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property

Performance

YTD
-32.65%
-32.65%
1 Month
-30.65%
-30.65%
3 Month
-23.25%
-23.25%
6 Month
-45.63%
-45.63%
1 Year
-56.58%
-56.58%

More News

Read More
BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Set to Discuss Lead Candidate Biomarker with FDA Leadership
Via Investor Brand Network
Exposures Product Safety
Clene Inc. (NASDAQ: CLNN) Presents Lead Candidate CNM-Au8(R) Updates, Latest Achievements at Top Investor Conferences
Via Investor Brand Network
Toxic Protein Could Be Behind the Development of Amyotrophic Lateral Sclerosis
Via Investor Brand Network
Disruptions in Purine Metabolism Cited in Parkinson’s Development
Via Investor Brand Network
Clene Inc. (NASDAQ: CLNN) Closes $7.3 Million Registered Direct Offering and Concurrent Private Placements
Via Investor Brand Network
BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Announces Participation at Two Upcoming Investor Conferences
Via Investor Brand Network
BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Closes on Direct Offering, Concurrent Private Placements Totaling $7.3M
Via Investor Brand Network
Exposures Product Safety
IBN Coverage: Clene (NASDAQ: CLNN) Announces Series of Direct Offerings, Concurrent Private Placements
Via NewMediaWire
BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces Series of Direct Offerings, Concurrent Private Placements Totaling $7.3M
Via Investor Brand Network
IBN Coverage: Clene (NASDAQ: CLNN) to Discuss CNM-Au8(R) Data FDA Leadership
Via NewMediaWire
Exposures Product Safety
Clene Inc. (NASDAQ: CLNN) to Discuss Lead Candidate CNM-Au8(R) Biomarker, Clinical Data for ALS with Food and Drug Administration Leadership
Via Investor Brand Network
Exposures Product Safety
BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Announces Upcoming In-Person FDA Meeting to Discuss CNM-Au8
Via Investor Brand Network
Exposures Product Safety
Does Multiple Sclerosis Reduce Risk of Developing Dementia?
Via Investor Brand Network
Clene Inc. (NASDAQ: CLNN) Management Presenting Recent Achievements, CNM-Au8(R) Results, at H.C. Wainwright Conference
Via Investor Brand Network
Clene Inc. (NASDAQ: CLNN) Seeks to Transform Neurodegenerative Disorder Treatments, with Rise in Prevalence and Associated Markets
Via Investor Brand Network
Why Argan Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
Via Benzinga
BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Management to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Via Investor Brand Network
BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Positioned as Leader in Addressing Neurodegenerative Diseases
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Clene Inc.’s (NASDAQ: CLNN) CEO Discusses Company’s Mission, CNM-Au8(R) Trial Results, and Future Plans on BioMedWire Podcast
Via Investor Brand Network
Clene Inc.’s (NASDAQ: CLNN) CNM-Au8(R) Affects Key Biomarkers and Long-term Survival in ALS Trials
Via Investor Brand Network
Exposures Product Safety
UCSF Team Tests New Drug That Could Reverse Multiple Sclerosis
Via Investor Brand Network
Antioxidants in Seaweed Could Help in Forestalling Parkinson’s Disease
Via Investor Brand Network
Clene Inc.’s (NASDAQ: CLNN) Makes Significant Strides in Developing its Lead Agent, CNM-Au8(R), to Address Neurodegenerative Conditions
Via Investor Brand Network
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.